Clinical Rheumatology

, Volume 29, Issue 6, pp 677–681 | Cite as

Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-α therapy: a case series

  • Kimberly MorishitaEmail author
  • Ross Petty
  • Robyn Cairns
  • Roxana Bolaria
  • David Cabral
  • Stuart Turvey
Brief Report


Anti-tumor necrosis factor-α (anti-TNF-α) agents are widely used to treat children with juvenile idiopathic arthritis (JIA) whose disease is resistant to conventional therapy. Although generally well tolerated, use of these agents has been associated with an increased risk of infection. In particular, in patients treated with anti-TNF-α agents, there is an increased susceptibility to infection by intracellular organisms such as tuberculosis, and common infections may present atypically or be more severe. We report four cases of serious musculoskeletal infections among 31 children with JIA being treated with anti-TNF-α agents, two of which were secondary to group A β-hemolytic Streptococcus.


Anti-tumor necrosis factor-α Biologics Infections Juvenile idiopathic arthritis 





  1. 1.
    Carrasco R, Smith JA, Lovell D (2004) Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs 6:137–146CrossRefPubMedGoogle Scholar
  2. 2.
    Stokes DG, Kremer JM (2003) Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum 33:1–18CrossRefPubMedGoogle Scholar
  3. 3.
    Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148–155CrossRefPubMedGoogle Scholar
  4. 4.
    Strangfeld A, Listing J (2006) Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 20:1181–1195CrossRefPubMedGoogle Scholar
  5. 5.
    Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265CrossRefPubMedGoogle Scholar
  6. 6.
    Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810–820CrossRefPubMedGoogle Scholar
  7. 7.
    Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–769CrossRefPubMedGoogle Scholar
  8. 8.
    Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096–3106CrossRefPubMedGoogle Scholar
  9. 9.
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285CrossRefPubMedGoogle Scholar
  10. 10.
    Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84:291–302CrossRefGoogle Scholar
  11. 11.
    Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122–2127CrossRefPubMedGoogle Scholar
  12. 12.
    Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 42:617–621CrossRefGoogle Scholar
  13. 13.
    Salvana EM, Salata RA (2009) Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 22(2):274–90CrossRefPubMedGoogle Scholar
  14. 14.
    Elwood RL, Pelszynski MM, Corman LI (2003) Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept. Pediatr Infect Dis J 22:286–288CrossRefPubMedGoogle Scholar
  15. 15.
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D et al (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30:2563–2571PubMedGoogle Scholar
  16. 16.
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602CrossRefPubMedGoogle Scholar
  17. 17.
    van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL et al (2003) Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12-week, phase II study. Ann Rheum Dis 62:1168–1177CrossRefPubMedGoogle Scholar
  18. 18.
    Leombruno JP, Einarson TR, Keystone EC (2008) The safety of anti-Tumor Necrosis Factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68(7):1136–1145CrossRefPubMedGoogle Scholar
  19. 19.
    Fitch PG, Cron RQ (2006) Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha. J Rheumatol 33:825, author reply 826–7PubMedGoogle Scholar
  20. 20.
    Kane D, Balint PV, Wood F, Sturrock RD (2003) Early diagnosis of pyomyositis using clinic-based ultrasonography in a patient receiving infliximab therapy for Behcet's disease. Rheumatology (Oxford) 42:1564–1565CrossRefGoogle Scholar
  21. 21.
    Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB et al (2003) Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 167:1279–1282CrossRefPubMedGoogle Scholar
  22. 22.
    Myers A, Clark J, Foster H (2002) Tuberculosis and treatment with infliximab. N Engl J Med 346:623–626CrossRefPubMedGoogle Scholar
  23. 23.
    Armbrust W, Kamphuis SS, Wolfs TW, Fiselier TJ, Nikkels PG, Kuis W et al (2004) Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 43:527–529CrossRefGoogle Scholar
  24. 24.
    Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G et al (2009) Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford) 48:978–986CrossRefGoogle Scholar
  25. 25.
    Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC et al (2003) Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 48:218–226CrossRefPubMedGoogle Scholar
  26. 26.
    Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D et al (2009) Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 68(4):519–525CrossRefPubMedGoogle Scholar
  27. 27.
    Sauer ST, Farrell E, Geller E, Pizzutillo PD (2004) Septic arthritis in a patient with juvenile rheumatoid arthritis. Clin Orthop Relat Res 418:219–221CrossRefPubMedGoogle Scholar
  28. 28.
    Feder HM Jr, Lawrence C (1999) Group A streptococcal multifocal septic arthritis: a case report. Clin Pediatr (Phila) 38:481–483CrossRefGoogle Scholar
  29. 29.
    Nelson JD (1972) The bacterial etiology and antibiotic management of septic arthritis in infants and children. Pediatrics 50:437–440PubMedGoogle Scholar
  30. 30.
    Mills WJ, Mosca VS, Nizet V (1996) Orthopaedic manifestations of invasive group A streptococcal infections complicating primary varicella. J Pediatr Orthop 16:522–528PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2010

Authors and Affiliations

  • Kimberly Morishita
    • 1
    • 5
    Email author
  • Ross Petty
    • 1
  • Robyn Cairns
    • 4
  • Roxana Bolaria
    • 3
  • David Cabral
    • 1
  • Stuart Turvey
    • 2
  1. 1.Division of Rheumatology, British Columbia’s Children’s HospitalUniversity of British ColumbiaVancouverCanada
  2. 2.Division of Infectious and Immunological Diseases, British Columbia’s Children’s HospitalUniversity of British ColumbiaVancouverCanada
  3. 3.Department of Pediatrics, British Columbia’s Children’s HospitalUniversity of British ColumbiaVancouverCanada
  4. 4.Department of Radiology, British Columbia’s Children’s HospitalUniversity of British ColumbiaVancouverCanada
  5. 5.Division of RheumatologyBritish Columbia’s Children’s HospitalVancouverCanada

Personalised recommendations